JP4698842B2 - 両親媒性シクロデキストリン、組織的系を溶解して疎水性分子を組み込むための、前記シクロデキストリンの調製及び使用 - Google Patents

両親媒性シクロデキストリン、組織的系を溶解して疎水性分子を組み込むための、前記シクロデキストリンの調製及び使用 Download PDF

Info

Publication number
JP4698842B2
JP4698842B2 JP2000615663A JP2000615663A JP4698842B2 JP 4698842 B2 JP4698842 B2 JP 4698842B2 JP 2000615663 A JP2000615663 A JP 2000615663A JP 2000615663 A JP2000615663 A JP 2000615663A JP 4698842 B2 JP4698842 B2 JP 4698842B2
Authority
JP
Japan
Prior art keywords
formula
derivative according
cyclodextrin
group
nhco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000615663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002543249A (ja
JP2002543249A5 (enExample
Inventor
ラシェル・オーズリー−ヴェルティ
ブリュノ・ペルリ
フローレンス・ドジェダイニ−ピラール
Original Assignee
コミッサリア ア レネルジー アトミーク エ オ ゼネルジ ザルタナテイヴ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コミッサリア ア レネルジー アトミーク エ オ ゼネルジ ザルタナテイヴ filed Critical コミッサリア ア レネルジー アトミーク エ オ ゼネルジ ザルタナテイヴ
Publication of JP2002543249A publication Critical patent/JP2002543249A/ja
Publication of JP2002543249A5 publication Critical patent/JP2002543249A5/ja
Application granted granted Critical
Publication of JP4698842B2 publication Critical patent/JP4698842B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
JP2000615663A 1999-04-29 2000-04-26 両親媒性シクロデキストリン、組織的系を溶解して疎水性分子を組み込むための、前記シクロデキストリンの調製及び使用 Expired - Fee Related JP4698842B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR99/05460 1999-04-29
FR9905460A FR2792942B1 (fr) 1999-04-29 1999-04-29 Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes
PCT/FR2000/001102 WO2000066635A1 (fr) 1999-04-29 2000-04-26 Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes

Publications (3)

Publication Number Publication Date
JP2002543249A JP2002543249A (ja) 2002-12-17
JP2002543249A5 JP2002543249A5 (enExample) 2011-02-17
JP4698842B2 true JP4698842B2 (ja) 2011-06-08

Family

ID=9545038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000615663A Expired - Fee Related JP4698842B2 (ja) 1999-04-29 2000-04-26 両親媒性シクロデキストリン、組織的系を溶解して疎水性分子を組み込むための、前記シクロデキストリンの調製及び使用

Country Status (7)

Country Link
US (1) US6858723B1 (enExample)
EP (1) EP1177217B1 (enExample)
JP (1) JP4698842B2 (enExample)
AT (1) ATE279446T1 (enExample)
DE (1) DE60014885T2 (enExample)
FR (1) FR2792942B1 (enExample)
WO (1) WO2000066635A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022100A1 (en) * 2002-08-15 2004-03-18 Yunqing Liu Soild nano pharmaceutical formulation and preparation method thereof
KR20140070676A (ko) * 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
FR2850972B1 (fr) * 2003-02-07 2005-03-11 Commissariat Energie Atomique Derives de per(3,6-anhydro) cyclodextrines, leur preparation et leur utilisation pour vehiculer des elements metalliques vers des cibles biologiques ou pour decontaminer des cibles ou fluides biologiques
FR2861396B1 (fr) * 2003-10-24 2005-12-16 Commissariat Energie Atomique Derives amphiphiles de cyclodextrines,leur procede de preparation et leurs utilisations
CN1894283B (zh) * 2003-12-18 2012-07-04 西巴特殊化学品控股有限公司 反应性多糖衍生物、其制备及其用途
EP1735326A4 (en) * 2004-01-29 2011-04-20 Pinnacle Pharmaceuticals BETA-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST LETHAL ANTHRAX TOXIN
CN101151037A (zh) * 2005-01-28 2008-03-26 平纳克尔医药股份有限公司 作为抗菌剂的β-环糊精衍生物
EP2023896B8 (en) * 2006-05-19 2016-09-14 Viroblock SA A composition for inactivating an enveloped virus
FR2907455A1 (fr) * 2006-10-18 2008-04-25 Commissariat Energie Atomique Oligosaccharides cycliques,notamment derives de cyclodextrines amphiphiles,substitues par un ou plusieurs groupements polycycles naturels,tels que les triterpenoides.
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
FR2919872B1 (fr) * 2007-08-10 2009-12-18 Commissariat Energie Atomique Derives de cyclodextrines
JP5364923B2 (ja) * 2009-01-28 2013-12-11 学校法人福岡大学 多機能性シクロデキストリン誘導体、その包接化合物およびそれらの製造方法。
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9051479B2 (en) * 2012-10-12 2015-06-09 Empire Technology Development Llc Paints and coatings containing cyclodextrin additives
CN105392804B (zh) * 2013-08-09 2018-07-10 生物辐射实验室股份有限公司 采用修饰的环糊精的蛋白质检测
TW202009013A (zh) * 2018-08-14 2020-03-01 優你康光學股份有限公司 具有功能性成分的隱形眼鏡及其產品
US20220362401A1 (en) * 2019-09-20 2022-11-17 The University Of Kitakyushu Particles, method for producing particles, drug, method for producing drug, and anti-cancer agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681868A1 (fr) * 1991-09-30 1993-04-02 Sederma Sa Nouvelles substances amphiphiles derivees de cyclodextrines et leur utilisation dans des compositions cosmetiques.
FR2726765B1 (fr) 1994-11-14 1996-12-20 Cis Bio Int Compositions radiopharmaceutiques comprenant un complexe d'inclusion d'une cyclodextrine et d'un acide gras radiohalogene
FR2736056B1 (fr) * 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
WO2002055562A2 (en) * 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials

Also Published As

Publication number Publication date
EP1177217B1 (fr) 2004-10-13
ATE279446T1 (de) 2004-10-15
JP2002543249A (ja) 2002-12-17
EP1177217A1 (fr) 2002-02-06
DE60014885D1 (de) 2004-11-18
FR2792942B1 (fr) 2001-06-08
FR2792942A1 (fr) 2000-11-03
DE60014885T2 (de) 2005-10-27
WO2000066635A1 (fr) 2000-11-09
US6858723B1 (en) 2005-02-22

Similar Documents

Publication Publication Date Title
US6858723B1 (en) Amphiphile cyclodextrins, preparation and use thereof for solubilizing organized systems and incorporating hydrophobic molecules
Auzély-Velty et al. Micellization of hydrophobically modified cyclodextrins. 1. Micellar structure
AU2016257431B2 (en) Ultrasmall nanoparticles and methods of making and using same
Toomari et al. Synthesis of the dendritic type β-cyclodextrin on primary face via click reaction applicable as drug nanocarrier
JP2003531930A (ja) 両親媒性大環状誘導体およびそれらの類似体
JPH047353B2 (enExample)
JP5477975B2 (ja) 新型キトサンベースハイブリッド巨大分子および巨大分子を製造または使用するための方法
Toomari et al. Fabrication of biodendrimeric β-cyclodextrin via click reaction with potency of anticancer drug delivery agent
US7812152B2 (en) Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof
Mendez-Ardoy et al. Monodisperse nanoparticles from self-assembling amphiphilic cyclodextrins: Modulable tools for the encapsulation and controlled release of pharmaceuticals
CN101531800A (zh) 癌细胞靶向诊断聚酰胺胺/碳纳米管复合材料的制备方法
CN111253505B (zh) 具有细胞靶向性的水溶性环糊精药物载体及其制备方法
WO2012153576A1 (ja) 内表面疎水化有機ナノチューブ、および同ナノチューブを用いた薬剤カプセル化物
EP3524276B1 (en) Biocompatible magnetic materials
CN111643678A (zh) 基于含巯基的两性离子多肽修饰的阿霉素衍生物、纳米胶束及其制备方法
CN108311709B (zh) 一种金纳米刺及其制备方法和应用
CN105963262A (zh) 一种新型两亲性果胶-双氢青蒿素纳米粒子的制备
JP2009514905A (ja) 磁気共鳴映像法用の造影剤としてのナノスケール粒子
Gutierrez‐Ulloa et al. Carbon nanotubes decorated with cationic carbosilane dendrons and their hybrids with nucleic acids
Cohen et al. Polycations. IX. Polyammonium derivatives of cyclodextrins: Syntheses and binding to organic oxyanions
CN118184992A (zh) 一种聚乙二醇-聚姜黄素-聚乙二醇偶联物、纳米颗粒及其制备方法
JP2006522853A (ja) カーボンナノチューブの周囲に自己組織化した光重合高分子、その製造方法及びその使用
CN111888460B (zh) 一种以达托霉素包载小分子疏水性药物的纳米载药胶束的制备方法
CN117700398A (zh) 一种具有蛋白冠调控功能的化合物及其纳米粒子和应用
JP3604390B2 (ja) 疎水性化合物を溶解するためおよびエナンチオマの純度を照査するためのモノ−３，６−アンヒドロシクロデキストリンの使用およびこれらのシクロデキストリンの調製方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101006

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101227

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110302

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees